The Poor Are Spending Less At McDonald’s
Fast-food giants built their empires on budget-conscious customers, but a troubling shift in spending habits is forcing McDonald's to rethink who actually shows up at the counter.
Fast-food giants built their empires on budget-conscious customers, but a troubling shift in spending habits is forcing McDonald's to rethink who actually shows up at the counter.
Five dividend payments hit accounts this month, but a Friday deadline separates investors who collect from those who wait another quarter. Not every yield on this list is what it appears to be.
NVIDIA just delivered its loudest quarter of the AI era, yet shares sit nearly 30% below their peak while B200 systems vanish from shelves faster than they ship. The bull case for a run…
SpaceX is pouring billions into AI while renting out its data centers to rivals, yet its models trail the competition and its consumer apps barely register. Something does not add up.
Five Nasdaq stocks share the same ex-dividend deadline this week, but they are not all worth buying for the same reason, and at least one comes with a warning flag that most income investors…
Tesla just posted record deliveries while its operating income collapsed and free cash flow went negative, yet BYD keeps selling more electrified vehicles than any company on earth. Which bet actually wins the next…
While seasoned hedge fund managers were quietly offloading their Microsoft shares, Bill Ackman made one of his biggest bets in years going the opposite direction, and he funded it by selling a stock that…
SpaceX just posted one of the most impressive earnings reports in recent memory, and the stock is getting crushed anyway. Two converging forces are threatening to swamp even the strongest bull case, and one…
AMD just posted a record quarter and the stock is tanking anyway, while NVIDIA is surging on a surprise deal that doubles as a direct shot at AMD's biggest ambitions.
UnitedHealth crushed Q2 estimates and doubled its buyback, yet the stock has pulled back since the report. Whether that dip signals a buying opportunity or a warning sign depends on one number management cannot…
AbbVie's blockbuster drugs are surging while a major acquisition looms, but a trailing P/E of 71 and one model pricing the stock nearly $50 below current levels raises a real question about whether the…
Seth Klarman spent four decades building a reputation for buying almost nothing, so when Baupost quietly planted a nine-figure flag in a payment network last quarter, the choice of which rail he picked over…
Eli Lilly just posted one of the most impressive quarters in pharmaceutical history, but the drug powering those numbers may not be what defines the company a decade from now. A billion-dollar bet on…
SpaceX delivered a blockbuster revenue beat in its first public earnings report, yet shares are cratering while every other space stock barely flinches. What spooked investors has nothing to do with rockets and everything…
Roblox stock shed more than 70% of its value in a year, yet Wall Street analysts and company insiders are moving in the opposite direction from the selloff. Here is what the conflicting signals…